Acasti pharma provides business update for the third quarter of fiscal 2022

Provides updates on key milestones: gtx-104 pk study remains on track for results to be reported in the first half of calendar 2022; gtx-102 and gtx-101 progressing on schedule

ACST Ratings Summary

ACST Quant Ranking